Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZOGSK)

Drug Name
(-)-CATECHINGALLATE Drug Info
Synonyms
(-)-Catechin gallate; 130405-40-2; (2S,3R)-2-(3,4-Dihydroxyphenyl)-5,7-dihydroxychroman-3-yl 3,4,5-trihydroxybenzoate; catechin gallate; UNII-0KT1FO6VO6; ent-Catechin 3-O-gallate; 0KT1FO6VO6; CHEMBL129451; CHEBI:76131; (2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; (2S,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); (-)-CATECHINGALLATE; Catechin gallate, (-)-; CCRIS 9303; Catechin gallateCG; (-)-Catechin gallate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6419835
ChEBI ID
CHEBI:76131
CAS Number
CAS 130405-40-2
TTD Drug ID
DMZOGSK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [2]
Morin DM2OGZ5 Discovery agent N.A. Investigative [2]
biochanin A DM0HPWY Discovery agent N.A. Investigative [2]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [2]
2-Hexadecynoic acid DMTFIPZ Discovery agent N.A. Investigative [3]
GALLOCATECHIN GALLATE DMX2084 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Fatty acid synthase (FASN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cerulenin DM6N4PR Weight loss MG43.5 Approved [4]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [2]
TVB-2640 DM19GUH Astrocytoma 2A00.0Y Phase 2 [5]
TVB-2640 DMP30SA Non-alcoholic fatty liver disease DB92 Phase 2 [6]
FAS1 DMAX2EW Fungal infection 1F29-1F2F Preclinical [7]
FSA2 DMLNRCI Fungal infection 1F29-1F2F Preclinical [7]
Morin DM2OGZ5 Discovery agent N.A. Investigative [2]
biochanin A DM0HPWY Discovery agent N.A. Investigative [2]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [2]
2-Hexadecynoic acid DMTFIPZ Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Plasmodium Enoyl-ACP reductase (Malaria fabI)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [8]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [9]
Nicotinamide-Adenine-Dinucleotide DM9LRKB N. A. N. A. Investigative [10]
Beta-D-Glucose DM5IHYP Discovery agent N.A. Investigative [10]
Morin DM2OGZ5 Discovery agent N.A. Investigative [2]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [2]
Thiolactomycin DMBAWDG Malaria 1F40-1F45 Investigative [8]
GALLOCATECHIN GALLATE DMX2084 Discovery agent N.A. Investigative [2]
Diazaborines DM5UFZX Discovery agent N.A. Investigative [11]
ISORHAMNETIN DMQ4Z6E Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [2]
Chrysin DM7V2LG Discovery agent N.A. Investigative [2]
Kaempferol DMHEMUB Discovery agent N.A. Investigative [2]
Morin DM2OGZ5 Discovery agent N.A. Investigative [2]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [2]
2-Hexadecynoic acid DMTFIPZ Discovery agent N.A. Investigative [3]
GALLOCATECHIN GALLATE DMX2084 Discovery agent N.A. Investigative [2]
ISORHAMNETIN DMQ4Z6E Discovery agent N.A. Investigative [2]
NADPH DM75Q34 Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Targeting Beta-secretase (BACE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [13]
E-2609 DMTNUJ8 Alzheimer disease 8A20 Phase 3 [14]
verubecestat DM4CGH5 Alzheimer disease 8A20 Phase 3 [15]
Lanabecestat DMFJLB6 Alzheimer disease 8A20 Phase 3 [16]
AZD3293 DMJQHXD Alzheimer disease 8A20 Phase 2/3 [17]
JNJ-54861911 DMGPJ5U Alzheimer disease 8A20 Phase 2/3 [16]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [13]
LY2886721 DMV14LM Alzheimer disease 8A20 Phase 2 [18]
LY3202626 DM7IFNB Alzheimer disease 8A20 Phase 2 [16]
Azd-3839 DM72FOD Alzheimer disease 8A20 Phase 1 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Beta-secretase (BACE) TT8JRS7 NOUNIPROTAC Inhibitor [1]
Fatty acid synthase (FASN) TT7AOUD FAS_HUMAN Inhibitor [2]
Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) TTHPFTS Q965D7_PLAFA Inhibitor [2]
Plasmodium Enoyl-ACP reductase (Malaria fabI) TTNX2CS Q965D5_PLAFA Inhibitor [2]
Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) TTBE4IR Q965D6_PLAFA Inhibitor [2]

References

1 Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3905-8.
2 Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
3 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
4 Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
5 Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
6 Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
7 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
8 Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
9 Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11 Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
12 Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92.
13 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
14 Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
15 BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
18 Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
19 Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.